Ariceum doses first patient with satoreotide
The treatment targets extensive stage small cell lung cancer and aims to boost therapeutic impact
Read Moreby John Pinching | Sep 7, 2023 | News | 0
The treatment targets extensive stage small cell lung cancer and aims to boost therapeutic impact
Read Moreby John Pinching | Jul 27, 2023 | News | 0
OCTP aims to demonstrate the lead candidate’s safety, tolerability and pharmacokinetic profile
Read Moreby John Pinching | Jun 21, 2023 | News | 0
During research there were not any clinically-relevant adverse events or psychotomimetic effects
Read Moreby John Pinching | Jun 21, 2023 | News | 0
Candidate is a cancer therapy that has been chemically modified with Avacta’s pre|CISION platform
Read Moreby John Pinching | Apr 5, 2023 | News | 0
Individual receives AVA6000 treatment as part of additional dose escalating study
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
